Pharmaceuticals, Biotechnology and Life Sciences
— Edasalonexent Global Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Fully Enrolled with Top-Line Results Expected in Q4 2020…
$37.6M in Rubraca® (rucaparib) net product revenue for Q3 2019, up 65% year over year Net product revenue increased 14%…
– Results Demonstrated Statistically Significant Improvement in Progression-Free Survival – – Data to be Submitted for Presentation at an Upcoming…
-Four-Year Update of the ECHELON-1 Trial Continues to Support Superior Clinical Activity of ADCETRIS in Combination with Chemotherapy when Compared…
Industry Veteran Marie E. Lamont Joins Inteliquet as Interim President and Chief Operating Officer DOVER, Del.–(BUSINESS WIRE)–Inteliquet, a leading provider…
DUBLIN–(BUSINESS WIRE)–The “Unituxin- Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. “Unituxin Drug Insight, 2019” highlights the drug…
Results of MIRA-1 and ORION-1 Phase 2b Studies Confirm Drug Product Profile and Provide Basis for Additional Patent Claims Nyxol…
Crescita had total revenue, consisting of product sales, out-licensing and services revenue, was $4,906 for the three months ended September 30, 2019, compared to $4,464 for the three months ended September 30, 2018.
Data to be shared during oral podium presentation at SITC 2019 Durable clinical benefit seen in multiple patients Abscopal responses…
HLS Therapeutics posted $1.9 million net loss in the third quarter 2019, compared to the same period last year, when it was compared to net loss of $19.7 million, boosted by Canadian-based clozaril sales in the last day of Q2.